- Home
- MGRX vs ENLV Comparison
MGRX vs ENLV Comparison
Compare MGRX & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- ENLV
- Stock Information
- Founded
- MGRX 2021
- ENLV 2005
- Country
- MGRX United States
- ENLV Israel
- Employees
- MGRX N/A
- ENLV N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- ENLV Health Care
- Exchange
- MGRX Nasdaq
- ENLV Nasdaq
- Market Cap
- MGRX 23.3M
- ENLV 25.3M
- IPO Year
- MGRX 2023
- ENLV 1995
- Fundamental
- Price
- MGRX $2.27
- ENLV $1.07
- Analyst Decision
- MGRX
- ENLV Strong Buy
- Analyst Count
- MGRX 0
- ENLV 2
- Target Price
- MGRX N/A
- ENLV $10.00
- AVG Volume (30 Days)
- MGRX 201.9K
- ENLV 1.1M
- Earning Date
- MGRX 11-13-2025
- ENLV 08-29-2025
- Dividend Yield
- MGRX N/A
- ENLV N/A
- EPS Growth
- MGRX N/A
- ENLV N/A
- EPS
- MGRX N/A
- ENLV N/A
- Revenue
- MGRX $516,030.00
- ENLV N/A
- Revenue This Year
- MGRX N/A
- ENLV N/A
- Revenue Next Year
- MGRX N/A
- ENLV N/A
- P/E Ratio
- MGRX N/A
- ENLV N/A
- Revenue Growth
- MGRX N/A
- ENLV N/A
- 52 Week Low
- MGRX $1.32
- ENLV $0.81
- 52 Week High
- MGRX $7.66
- ENLV $2.10
- Technical
- Relative Strength Index (RSI)
- MGRX 61.49
- ENLV 43.34
- Support Level
- MGRX $2.07
- ENLV $1.00
- Resistance Level
- MGRX $2.48
- ENLV $1.08
- Average True Range (ATR)
- MGRX 0.28
- ENLV 0.05
- MACD
- MGRX 0.01
- ENLV 0.00
- Stochastic Oscillator
- MGRX 67.51
- ENLV 53.85
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.